WST · 8-K · 20261029PR000118
Capital Expenditure Guidance
WEST PHARMACEUTICAL SERVICES INC · 2026-10-29 · Importance 73 · Surprise 76 · From source text
First-nine-month capital expenditures were $125.0 million, down from $209.8 million in the same 2025 period. Full-year 2026 capital spending guidance was reduced to $215 million–$220 million from the prior range of $250 million–$275 million. Accrued capital expenditures at September 30, 2026 were $28.3 million, compared with $38.1 million a year earlier.
Key facts
- West updated its full-year 2026 capital spending guidance to $215 million to $220 million, down from $250 million to $275 million. source
- West's capital expenditures were $125 million year to date through the third quarter of 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | — | West updated its full-year 2026 capital spending guidance to $215 million to $220 million, down from $250 million to $275 million. |